News and Updates

The FDA has approved the first targeted therapy for hypothalamic obesity caused by brain injury, offering new hope for patients with metabolic disorders.

Davenport University and Hurley Medical Center launch a new scholarship partnership to tackle staffing shortages and boost local nursing and health careers.

Q32 Bio is set to unveil 36-week Phase 2a trial results for bempikibart, a potential breakthrough therapy targeting the IL-7Rα pathway for autoimmune care.

Bayer joins forces with UCHealth, Children’s Hospital Colorado, and CU Anschutz to launch innovative clinical trials and accelerate medical breakthroughs.

Over $1.4 billion is flooding into AI-driven cardiovascular drug development. Discover how machine learning is accelerating heart disease therapy discovery.

Surgeons have successfully used teleoperated humanoid robots in live pre-clinical trials, marking a major leap forward for robotic-assisted surgery.

New research suggests guanfacine and N-acetylcysteine may help alleviate chronic fatigue and brain fog in Long COVID patients. Learn more about the study.

FDA leadership changes could shift regulatory priorities. Learn which policies, from accelerated approval to AI guidance, face potential revisions.

A new clinical trial shows that a novel liquid supplement significantly reduces LDL cholesterol, offering a promising new tool for heart health management.

Hansoh Pharmaceutical’s HS-20093 met primary endpoints in the ARTEMIS-008 trial, showing significant survival benefits for patients with SCLC.